RecruitingRecruiting
MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)
NCT06602648 · University of Florence
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults. Histological, Computational, and Molecular Pathology for Improved Diagnosis. (Mol-Mel). Work Package 3 (WP3)
About this study
The Mol-Mel study will focus on different tasks and for each task different investigations will be carried out:
* Standardization and tissue quality control: The quality of the samples will then be determined using hematoxylin \& eosin (HE)-staining. If any quality issue is detected feedback will be sent to the clinical center responsible for providing the sample
* Histopathology \& computational pathology: Melanoma samples will undergo a central pathology review and analysis of conventional prognostic staging parameters. Diagnostically challenging neoplasms will be included in an "inter-observer agreement" carried out by different pathologist.Melanoma samples will also be charactered by single and multi-plex IHC in whole sections and tissue microarrays (TMA), and subjected to automated digital quantification. Spatial proteomics by automated ultra-high content imaging/MACSima Imaging Cyclic Staining (MICS) technology enables simultaneous analysis of hundreds of marker antigens on a single sample. Hundreds of antigens for single sample will be analysed via "Automated ultra-high content imaging/MACSima Imaging Cyclic Staining" (MICS) that will be performed on the novel automated ultra-high content imaging platform MACSimaTM (Miltenyi Biotec).
* Comprehensive somatic, transcriptional and DNA methylation landscape and data integration: DNA and RNA will be extracted by FFPE melanoma samples and characterized using whole-exome sequencing (WES), single nucleotide polymorphism (SNP) and RNA sequencing (RNAseq) arrays on matched tumor/normal pairs of samples. Then recurrent somatic aberrations, DNA methylation subclasses and patterns of tumor evolution will be characterized.
* Pan-European digital second opinion platform: this last task will focus on creating a pan-european second opinion platofrom in order to facilitate standardization of melanoma diagnosis and to share knowledge about biomarkers, algorithms and subtype classification.
Eligibility criteria
Inclusion Criteria:
* adolescent and childhood patients (\< 20 years) or young adults (\< 30 years)
* histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification)
Exclusion criteria:
* adult patients (\> 30 years of age)
* patients without histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm
Study design
Enrollment target: 100 participants
Age groups: child, adult
Timeline
Starts: 2024-04-17
Estimated completion: 2026-11
Last updated: 2024-09-19
Primary outcomes
- • Primary objective - Hybrid taxonomy (From enrollment at the end of 32 months)
- • Primay objective - Histopathological and molecular features of pediatric melanoma (From enrollment at the end of 32 months)
Sponsor
University of Florence · other
With: Tubingen University Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Hospital Clinic of Barcelona, Istanbul University, University Of Perugia, German Cancer Research Center
Contacts & investigators
ContactDaniela Massi Professor · contact · daniela.massi@unifi.it · 3925536585
ContactDario Di Gangi Doctor · contact · dario.digangi@unifi.it · 3925536585
InvestigatorMassi Daniela · principal_investigator, University of Florence (UNIFI)
All locations (1)
University of FlorenceRecruiting
Florence, Italy, Italy